Parvin Asset Management LLC Invests $412,000 in Smith & Nephew plc (NYSE:SNN)

Parvin Asset Management LLC purchased a new stake in shares of Smith & Nephew plc (NYSE:SNN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 16,750 shares of the medical equipment provider's stock, valued at approximately $412,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Northern Trust Corp boosted its holdings in Smith & Nephew by 169.9% during the fourth quarter. Northern Trust Corp now owns 508,392 shares of the medical equipment provider's stock valued at $12,496,000 after acquiring an additional 320,054 shares during the period. Optiver Holding B.V. boosted its position in Smith & Nephew by 213.9% in the 4th quarter. Optiver Holding B.V. now owns 207,419 shares of the medical equipment provider's stock valued at $5,098,000 after buying an additional 141,337 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in Smith & Nephew during the 4th quarter worth $1,022,000. Syon Capital LLC grew its holdings in Smith & Nephew by 89.0% during the fourth quarter. Syon Capital LLC now owns 20,250 shares of the medical equipment provider's stock valued at $498,000 after purchasing an additional 9,534 shares during the period. Finally, Stifel Financial Corp increased its stake in Smith & Nephew by 19.5% during the 4th quarter. Stifel Financial Corp now owns 48,292 shares of the medical equipment provider's stock worth $1,187,000 after purchasing an additional 7,893 shares in the last quarter. Institutional investors own 25.64% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. StockNews.com raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. UBS Group downgraded shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. HSBC downgraded shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Canaccord Genuity Group lifted their price target on Smith & Nephew from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday. Finally, Hsbc Global Res lowered shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Six investment analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew Trading Down 1.0 %

Shares of SNN stock traded down $0.28 on Monday, hitting $28.34. The company had a trading volume of 205,505 shares, compared to its average volume of 813,265. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. Smith & Nephew plc has a twelve month low of $23.69 and a twelve month high of $32.00. The stock's 50-day moving average is $27.65 and its two-hundred day moving average is $26.29. The firm has a market cap of $12.41 billion, a P/E ratio of 13.13, a P/E/G ratio of 1.26 and a beta of 0.68.

Smith & Nephew Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be paid a $0.447 dividend. This represents a dividend yield of 2.5%. This is an increase from Smith & Nephew's previous semi-annual dividend of $0.29. The ex-dividend date of this dividend is Friday, March 28th. Smith & Nephew's payout ratio is currently 41.20%.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.